Company Profile
CorMedix Inc. Stock Price, News & Analysis
- Ticker:
- CRMD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.51 USD (+1.35%)
Close
Last updated: August 6, 2026
641M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CRMD closed up 1.35% at $7.51. No new same-company headline was identified in the current news window.
Company overview
Institutional Anti-Infective Company
CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
DefenCath
DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. It is the company’s largest commercial product.
Acquired Melinta Portfolio
The Melinta acquisition added marketed anti-infectives, including REZZAYO, and expanded CorMedix’s hospital-focused commercial organization.
Late-Stage Expansion Programs
CorMedix is developing REZZAYO for prophylaxis of invasive fungal disease after allogeneic stem-cell transplantation and DefenCath for patients receiving total parenteral nutrition.
Future catalysts
An FDA supplemental NDA submission for REZZAYO prophylaxis is expected in the second half of 2026.
A potential commercial launch of REZZAYO in the expanded prophylaxis indication is targeted for 2027.
The Phase 3 study of taurolidine and heparin catheter-lock solution in total parenteral nutrition patients is currently trending toward completion in 2028.
Recent news
- 01
- 02
- 03
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
Source: CorMedix Inc.
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CorMedix Inc. (CRMD)?
CorMedix Inc. (CRMD) most recently closed at 7.51 USD, a +1.35% move versus the previous session.
What is the market cap of CorMedix Inc. (CRMD)?
CorMedix Inc. currently has a market capitalization of 641M USD on BioPharmSignal.
What does CorMedix Inc. do?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care. DefenCath DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with...
On which exchange is CRMD stock listed?
CorMedix Inc. (CRMD) is associated with NASDAQ, United States, Biopharma.
What is Institutional?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
Which conditions is CorMedix Inc. targeting with Institutional?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care. DefenCath DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with...
How does CorMedix Inc. describe recent progress with Institutional?
An FDA supplemental NDA submission for REZZAYO prophylaxis is expected in the second half of 2026. A potential commercial launch of REZZAYO in the expanded prophylaxis indication is targeted for 2027. The Phase 3 study of taurolidine and heparin catheter-lock solution in total parenteral nutrition patients is currently trending toward completion in 2028.
What is Anti-Infective?
Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.